Brief: Innovent Biologics Says Third-Generation EGFR TKI Limertinib Received Approval From NMPA
25/04/2025 16:10
April 25 (Reuters) - Innovent Biologics Inc 1801.HK: THIRD-GENERATION EGFR TKI LIMERTINIB RECEIVED APPROVAL FROM NMPA Further company coverage: 1801.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis